STRIDES PHARMA SCIENCE LIMITED
STAR · ISIN: INE939A01011
STRIDES PHARMA SCIENCE LIMITED is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE939A01011.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
STRIDES PHARMA SCIENCE LIMITED - growth of ₹100
Growth of ₹100 invested on 2026-05-08, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-2.01%
3M
+7.07%
6M
+5.85%
1Y
+34.74%
3Y CAGR
+32.03%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
STRIDES PHARMA SCIENCE LIMITED - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-09-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-09-30.
F&O Sentiment
Nearest expiry: 2022-06-30 · As of 2022-06-30.
Corporate Actions
| Ex-Date | Type | Ratio | Details |
|---|---|---|---|
| 2024-12-06 | SPLIT | 0.459614 | implied_from_price |
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-08-28 | BULK | 10,00,000 |
| 2026-08-28 | BULK | 10,00,000 |
| 2026-08-28 | BLOCK | 10,00,000 |
| 2026-08-28 | BLOCK | 10,00,000 |
Frequently asked questions
What is STRIDES PHARMA SCIENCE LIMITED's 1-year and 3-year return?
STRIDES PHARMA SCIENCE LIMITED's 1-year price return is +34.74%. Its 3-year CAGR (annualized return) is +32.03%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is STRIDES PHARMA SCIENCE LIMITED's latest financial performance?
STRIDES PHARMA SCIENCE LIMITED's trailing-twelve-month (TTM) revenue as of 2026-09-30 is ₹5,213 Cr, with a TTM profit after tax of ₹637 Cr and an EBITDA margin of 17.54%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹66.91, with a 5-year EPS growth rate of 81.75% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is STRIDES PHARMA SCIENCE LIMITED's quality score?
STRIDES PHARMA SCIENCE LIMITED has a Punji quality score of 72.7 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do STRIDES PHARMA SCIENCE LIMITED's technical indicators show?
As of 2026-10-29, STRIDES PHARMA SCIENCE LIMITED's RSI (14-day) is 53.18 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of STRIDES PHARMA SCIENCE LIMITED?
As of 2026-09-30, STRIDES PHARMA SCIENCE LIMITED's shareholding is split across Promoter (29%), Public (71%), NonPromoterNonPublic (null%). Promoter holding of 29% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
What does the F&O market show for STRIDES PHARMA SCIENCE LIMITED?
As of 2022-06-30 (nearest expiry 2022-06-30), STRIDES PHARMA SCIENCE LIMITED's put-call ratio by open interest is 0.6046 - below 1, typically read as bullish positioning (more open interest on calls than puts). The max pain strike is ₹325, the price at which option writers as a group would owe the least to option buyers at expiry - a reference level some traders watch, not a price target. F&O positioning reflects derivatives-market sentiment over a specific expiry window, not a fundamental view on the company.
Has STRIDES PHARMA SCIENCE LIMITED seen any recent bulk or block deals?
Yes, as of 2026-08-28 - the most recent recorded deal was a BULK on 2026-08-28 for 10,00,000 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
What corporate actions has STRIDES PHARMA SCIENCE LIMITED announced recently?
The most recent corporate action for STRIDES PHARMA SCIENCE LIMITED is a SPLIT (0.459614) with an ex-date of 2024-12-06, for: implied_from_price. The ex-date is the cutoff - only shareholders who held the stock before this date qualify for the action (dividend, split, bonus, or rights issue, depending on type). Corporate actions typically adjust the stock's price and/or share count mechanically on the ex-date, which is why historical price charts are usually shown adjusted for these events.
Stock data · Not financial advice · Past performance does not indicate future returns